Bio-Techne has partnered with Autolomous to implement an electronic batch record system, AutoloMATE, at Bio-Techne’s GMP cellular manufacturing centre.
Through this partnership, Bio-Techne will be able to offer electronic records to therapeutic companies utilising its non-viral gene delivery system, TcBuster, or contract cellular manufacturing services alongside working with Autolomous to integrate further its analytical and manufacturing technologies within their platforms.
“Improving process control during the manufacture of novel cell-based therapies will further ensure that patient products meet the highest quality standards resulting in safer therapies,” said Dave Eansor, Bio-Techne’s Protein Sciences Segment President. “Adding this level of precision to our process monitoring represents another milestone as we deliver best-in-class gene editing and manufacturing capabilities to our clients.”
“This is an excellent development for Autolomous as we seek to extend our portfolio of users across Europe and the US and the diversity of products we can support. Implementation at Bio-Techne’s GMP manufacturing facility will showcase the flexibility of our solutions and its ability to support a variety of Cell & Gene Therapy Manufacturing workflows. This will be our first deployment in the US which is particularly exciting for us”, said Alexander Seyf, CEO of Autolomous.